As more high-ticket biologic drugs reach the marketplace, the biotech industry may be increasingly beset by counterfeiters. Do regulators and law enforcement have the tools they need?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Harper, J. Counterfeit Medicines, Survey Report (Council of Europe Publishing, Strasbourg, France, 2006). http://book.coe.int/EN/ficheouvrage.php?PAGEID=36&lang=EN&produit_aliasid=2025
Eban, K. Dangerous Doses: How Counterfeiters Are Contaminating America's Drug Supply (Harcourt, Orlando, Florida, USA, 2005).
Newton, P.N. et al. Lancet Infect. Dis. 6, 602–613 (2006).
Pitts, P.J. (ed.). Coincidence or Crisis? Prescription Medicine Counterfeiting (The Stockholm Network, London, 2006). http://www.stockholm-network.org/downloads/publications/d41d8cd9-Coincidence%20or%20Crisis%20Final.pdf
Saul, S. Subpoenas seek data on resales of drugs. New York Times 9 April 2005.
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Counterfeit pharmaceuticals: Murder by medicine
Rising drug costs prompt new uses for old pills
Web links
Rights and permissions
About this article
Cite this article
Sheridan, C. Bad medicine. Nat Biotechnol 25, 707–709 (2007). https://doi.org/10.1038/nbt0707-707
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0707-707
This article is cited by
-
Physical unclonable functions generated through chemical methods for anti-counterfeiting
Nature Reviews Chemistry (2017)
-
Availability and quality of illegitimate somatropin products obtained from the Internet
International Journal of Clinical Pharmacy (2017)
